Antineoplastic Combined Chemotherapy ProtocolsAntineoplastic AgentsDoxorubicinCyclophosphamideCombined Modality TherapyOsteosarcomaCisplatinDisease-Free SurvivalTreatment OutcomeVincristineChemotherapy, AdjuvantPrognosisPrecursor Cell Lymphoblastic Leukemia-LymphomaRetrospective StudiesClinical ProtocolsAntibiotics, AntineoplasticAntineoplastic Agents, PhytogenicDrug Administration ScheduleBreast NeoplasmsNeoplasmsEtoposidePaclitaxelAntineoplastic Agents, AlkylatingNeoadjuvant TherapyLung NeoplasmsAntimetabolites, AntineoplasticMethotrexateSurvival AnalysisSurvival RateNeoplasm StagingTime FactorsDrug Resistance, NeoplasmDose-Response Relationship, DrugCell Line, TumorVinblastineCarboplatinTaxoidsBleomycinDeoxycytidineOrganoplatinum CompoundsDrug Screening Assays, AntitumorCytarabineIfosfamideClinical Trials as TopicFollow-Up StudiesNeoplasm Recurrence, LocalInduction ChemotherapyApoptosisAnthracyclinesOvarian NeoplasmsProspective StudiesNeoplasm MetastasisDrug SynergismVomitingAdenocarcinomaNauseaDaunorubicinTumor Cells, CulturedCarcinoma, Non-Small-Cell LungCamptothecinCarmustineCell SurvivalInfusions, IntravenousRandomized Controlled Trials as TopicColorectal NeoplasmsXenograft Model Antitumor AssaysBrain NeoplasmsLymphoma, Non-HodgkinSalvage TherapyMitomycinRadiotherapyChemotherapy, Cancer, Regional PerfusionDacarbazineLomustineAntibodies, Monoclonal, HumanizedNeutropeniaDrug EvaluationLeukopeniaBone NeoplasmsTransplantation, AutologousMelphalanAntibodies, MonoclonalMice, NudeRecurrenceLiver NeoplasmsTesticular NeoplasmsAdministration, OralRadiotherapy, AdjuvantMitoxantroneLeukemia P388Kaplan-Meier EstimateHodgkin DiseaseCell ProliferationDouble-Blind MethodAntineoplastic ProtocolsColonic NeoplasmsLymphomaTumor Markers, BiologicalGalliumDrug Evaluation, Preclinical